Jubilant Pharmova net profit rises 52 percent at Rs 310 crore in Q3
New Delhi: Drug firm Jubilant Pharmova on Friday reported a 52.34 per cent rise in its consolidated net profit to Rs 309.83 crore for the quarter ended in December.
The company had posted a net profit of Rs 203.38 crore for the corresponding period of the previous financial year, Jubilant Pharmova said in a filing to BSE.
Consolidated total revenue from operations of the company stood at Rs 1,771.34 crore for the quarter under consideration. It was Rs 1,517.98 crore for the same period a year ago, it added.
"Q3''FY21 has witnessed a substantial improvement over the previous quarter despite the continued adverse impact of the COVID-19 pandemic," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman and Managing Director Hari S Bhartia said in a statement.
Pharma business delivered strong performance led by contract development and manufacturing organisation (CDMO) and Generics. We continue to see new business opportunities in CDMO, Generics and Specialty Pharma segments, they added.
Read also: Jubilant Pharma, Aavis launch Hydroxychloroquine Sulfate tablets in US
The company''s performance in the Life Science Ingredients (LSI) business has been better due to good demand and improved select products pricing. Contract Research and Development Services business witnessed strong year-on-year growth in revenues led by healthy demand from customers, the statement said.
"We continue to expect strong performance in our businesses in Q4''FY21," it added.
Read also: Jubilant Therapeutics, The Wistar Institute join hands for COVID-19 research
